Arbutus Biopharma Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Arbutus Biopharma Corporation income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue6.1718.1439.0210.996.916.015.95
Cost of Revenue54.0473.7084.4165.5047.480.0057.93
Gross Profit-47.87-55.56-45.3910.99-40.576.01-51.99
Operating Expenses
Research & Development54.0473.7084.4165.5049.3457.6057.93
Selling, General & Administrative22.1122.4817.8317.1414.8517.7316.00
Operating Expenses76.1522.4817.8382.6464.72-149.9176.12
Operating Income-69.97-78.03-63.22-71.65-57.81-71.35-70.17
Other Income/Expense
Interest Income6.595.692.190.130.740.003.05
Interest Expense0.14-0.46-1.732.86-4.010.000.23
Other Income/Expense-6.39-0.04-2.26-1.873.0066.196.01
Income
Income Before Tax-69.92-72.85-65.01-76.25-63.73-166.38-61.34
Income Tax Expense0.000.004.440.000.00-12.66-4.28
Net Income-69.92-72.85-69.46-76.25-63.75-153.72-57.06
Net Income - Continuous Operations-69.92-72.85-69.46-76.250.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-68.40-76.63-61.80-71.64-57.76-162.52-58.94
EBIT-69.78-78.03-63.22-73.39-59.72-164.27-61.12
Depreciation & Amortization1.381.401.431.751.982.032.18
Earnings Per Share
Basic EPS----1.00-1.00--1.00
Diluted EPS----1.00-1.00-3.00-1.00
Basic Shares Outstanding185.61165.96150.94106.2475.8457.0955.30
Diluted Shares Outstanding185.61165.96150.94106.2475.8437.0455.30